Biofourmis Announces Expanded Digital Clinical Trials Solution
Biofourmis has announced the release of its expanded Digital Clinical Trials solution within the Biofourmis platform for biopharma and other life sciences companies.
The solution includes a technology-enabled, scalable platform and services that support digital tools enablement, trial decentralization, safety monitoring, personalized care, participant recruitment, and increased access to treatment options for patients. According to the company, it can help sponsors and researchers accelerate clinical development with remote data collection and novel digital endpoints from Biofourmis' library of biomarkers across multiple therapeutic areas.
The expanded solution offers a more holistic workflow, new data management automations, and integration of essential clinical trial documentation, participant scheduling, and data collection elements. Because the artificial intelligence (AI)-powered platform is configurable, study start-up timelines can be reduced. The connected platform integrates with 40+ devices, enabling study teams the freedom to select the right device for the right disease area.
Biopharma companies can also tap into Biofourmis' principal investigator (PI) network. The network includes experienced PIs from leading academic medical centers. Health systems that already use the Biofourmis platform for technology-enabled care delivery at home can expand their clinical research initiatives by leveraging the connected platform to include the Digital Clinical Trials functionality.
"Leveraging digital tools and automating and accelerating trial processes for both researchers and participants can increase the likelihood that endpoints will be reached sooner, which lowers costs and simplifies tasks for everyone involved," said Biofourmis COO Jaydev Thakkar in a press release. "More importantly, shorter trials with more meaningful results mean that groundbreaking new therapies can be discovered and developed faster to improve outcomes for patients worldwide."
Reference
Biofourmis Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution. (2023, September 18). Cision PR Newswire.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
